|
1
|
Matthay KK, Maris JM, Schleiermacher G,
Nakagawara A, Mackall CL, Diller L and Weiss WA: Neuroblastoma. Nat
Rev Dis Primers. 2:160782016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang RK and Sondel PM: Anti-GD2 strategy
in the treatment of neuroblastoma. Drugs Future. 35:6652010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maris JM: Recent advances in
neuroblastoma. N Engl J Med. 362:2202–2211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fish JD and Grupp SA: Stem cell
transplantation for neuroblastoma. Bone Marrow Transplant.
41:159–165. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wagner LM and Danks MK: New therapeutic
targets for the treatment of high-risk neuroblastoma. J Cell
Biochem. 107:46–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ren N, Atyah M, Chen WY and Zhou CH: The
various aspects of genetic and epigenetic toxicology: Testing
methods and clinical applications. J Transl Med. 15:1102017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bianco P, Robey PG and Simmons PJ:
Mesenchymal stem cells: Revisiting history, concepts, and assays.
Cell Stem Cell. 2:313–319. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hwang NS, Zhang C, Hwang YS and Varghese
S: Mesenchymal stem cell differentiation and roles in regenerative
medicine. Wiley Interdiscip Rev Syst Biol Med. 1:97–106. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pittenger MF, Mackay AM, Beck SC, Jaiswal
RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S and
Marshak DR: Multilineage potential of adult human mesenchymal stem
cells. Science. 284:143–147. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Granero-Molto F, Weis JA, Longobardi L and
Spagnoli A: Role of mesenchymal stem cells in regenerative
medicine: Application to bone and cartilage repair. Expert Opin
Biol Ther. 8:255–268. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Savkovic V, Li H, Seon JK, Hacker M, Franz
S and Simon JC: Mesenchymal stem cells in cartilage regeneration.
Curr Stem Cell Res Ther. 9:469–488. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dezawa M, Ishikawa H, Itokazu Y, Yoshihara
T, Hoshino M, Takeda S, Ide C and Nabeshima Y: Bone marrow stromal
cells generate muscle cells and repair muscle degeneration.
Science. 309:314–317. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakamizo A, Marini F, Amano T, Khan A,
Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, et
al: Human bone marrow-derived mesenchymal stem cells in the
treatment of gliomas. Cancer Res. 65:3307–3318. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Duan X, Guan H, Cao Y and Kleinerman ES:
Murine bone marrow-derived mesenchymal stem cells as vehicles for
interleukin-12 gene delivery into Ewing sarcoma tumors. Cancer.
115:13–22. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Studeny M, Marini FC, Champlin RE,
Zompetta C, Fidler IJ and Andreeff M: Bone marrow-derived
mesenchymal stem cells as vehicles for interferon-beta delivery
into tumors. Cancer Res. 62:3603–3608. 2002.PubMed/NCBI
|
|
16
|
Ozawa K, Sato K, Oh I, Ozaki K, Uchibori
R, Obara Y, Kikuchi Y, Ito T, Okada T, Urabe M, et al: Cell and
gene therapy using mesenchymal stem cells (MSCs). J Autoimmun.
30:121–127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
1Javazon EH, Beggs KJ and Flake AW:
Mesenchymal stem cells: Paradoxes of passaging. Exp Hematol.
32:414–425. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xin H, Kanehira M, Mizuguchi H, Hayakawa
T, Kikuchi T, Nukiwa T and Saijo Y: Targeted delivery of CX3CL1 to
multiple lung tumors by mesenchymal stem cells. Stem Cells.
25:1618–1626. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Loebinger MR and Janes SM: Stem cells as
vectors for antitumour therapy. Thorax. 65:362–369. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Loebinger MR, Eddaoudi A, Davies D and
Janes SM: Mesenchymal stem cell delivery of TRAIL can eliminate
metastatic cancer. Cancer Res. 69:4134–4142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pitti RM, Marsters SA, Ruppert S, Donahue
CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2
ligand, a new member of the tumor necrosis factor cytokine family.
J Biol Chem. 271:12687–12690. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kelley SK and Ashkenazi A: Targeting death
receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol.
4:333–339. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wiley SR, Schooley K, Smolak PJ, Din WS,
Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA,
et al: Identification and characterization of a new member of the
TNF family that induces apoptosis. Immunity. 3:673–682. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Herbst RS, Eckhardt SG, Kurzrock R,
Ebbinghaus S, ODwyer PJ, Gordon MS, Novotny W, Goldwasser MA,
Tohnya TM, Lum BL, et al: Phase I dose-escalation study of
recombinant human Apo2L/TRAIL, a dual proapoptotic receptor
agonist, in patients with advanced cancer. J Clin Oncol.
28:2839–2846. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Soria JC, Smit E, Khayat D, Besse B, Yang
X, Hsu CP, Reese D, Wiezorek J and Blackhall F: Phase 1b study of
dulanermin (recombinant human Apo2L/TRAIL) in combination with
paclitaxel, carboplatin, and bevacizumab in patients with advanced
non-squamous non-small-cell lung cancer. J Clin Oncol.
28:1527–1533. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yuan Z, Kolluri KK, Sage EK, Gowers KH and
Janes SM: Mesenchymal stromal cell delivery of full-length tumor
necrosis factor-related apoptosis-inducing ligand is superior to
soluble type for cancer therapy. Cytotherapy. 17:885–896. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sheard MA, Asgharzadeh S, Liu Y, Lin TY,
Wu HW, Ji L, Groshen S, Lee DA and Seeger RC: Membrane-bound TRAIL
supplements natural killer cell cytotoxicity against neuroblastoma
cells. J Immunother. 36:319–329. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mueller LP, Luetzkendorf J, Widder M,
Nerger K, Caysa H and Mueller T: TRAIL-transduced multipotent
mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in
selected CRC cell lines in vitro and in vivo. Cancer Gene Ther.
18:229–239. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sage EK, Kolluri KK, McNulty K, Lourenco
Sda S, Kalber TL, Ordidge KL, Davies D, Gary Lee YC, Giangreco A
and Janes SM: Systemic but not topical TRAIL-expressing mesenchymal
stem cells reduce tumour growth in malignant mesothelioma. Thorax.
69:638–647. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Loi M, Becherini P, Emionite L, Giacomini
A, Cossu I, Destefanis E, Brignole C, Di Paolo D, Piaggio F, Perri
P, et al: sTRAIL coupled to liposomes improves its pharmacokinetic
profile and overcomes neuroblastoma tumour resistance in
combination with Bortezomib. J Control Release. 192:157–166. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tong HX, Lu CW, Wang QS and Ma LY:
Combination of IFNgamma and chemotherapeutic agents increase TRAIL
sensitivity of neuroblastoma cell lines. Eur J Pediatr Surg.
21:304–309. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Brignole C, Marimpietri D, Pastorino F,
Nico B, Di Paolo D, Cioni M, Piccardi F, Cilli M, Pezzolo A,
Corrias MV, et al: Effect of bortezomib on human neuroblastoma cell
growth, apoptosis, and angiogenesis. J Natl Cancer Inst.
98:1142–1157. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Braekeveldt N, Wigerup C, Gisselsson D,
Mohlin S, Merselius M, Beckman S, Jonson T, Börjesson A, Backman T,
Tadeo I, et al: Neuroblastoma patient-derived orthotopic xenografts
retain metastatic patterns and geno- and phenotypes of patient
tumours. Int J Cancer. 136:E252–E261. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chaiwatanasirikul KA and Sala A: The
tumour-suppressive function of CLU is explained by its localisation
and interaction with HSP60. Cell Death Dis. 2:e2192011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fujita T, Igarashi J, Okawa ER, Gotoh T,
Manne J, Kolla V, Kim J, Zhao H, Pawel BR, London WB, et al: CHD5,
a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J
Natl Cancer Inst. 100:940–949. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang C, Liu Z, Woo CW, Li Z, Wang L, Wei
JS, Marquez VE, Bates SE, Jin Q, Khan J, et al: EZH2 Mediates
epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU,
RUNX3, and NGFR. Cancer Res. 72:315–324. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Corvetta D, Chayka O, Gherardi S, DAcunto
CW, Cantilena S, Valli E, Piotrowska I, Perini G and Sala A:
Physical interaction between MYCN oncogene and polycomb repressive
complex 2 (PRC2) in neuroblastoma: Functional and therapeutic
implications. J Biol Chem. 288:8332–8341. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dvorkina M, Nieddu V, Chakelam S, Pezzolo
A, Cantilena S, Leite AP, Chayka O, Regad T, Pistorio A, Sementa
AR, et al: A promyelocytic leukemia protein-thrombospondin-2 axis
and the risk of relapse in neuroblastoma. Clin Cancer Res.
22:3398–3409. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Valentijn LJ, Koster J, Zwijnenburg DA,
Hasselt NE, van Sluis P, Volckmann R, van Noesel MM, George RE,
Tytgat GA, Molenaar JJ, et al: TERT rearrangements are frequent in
neuroblastoma and identify aggressive tumors. Nat Genet.
47:1411–1414. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shalaby T and Grotzer MA: MYC as
therapeutic target for embryonal tumors: Potential and challenges.
Curr Cancer Drug Targets. 16:2–21. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Walczak H, Miller RE, Ariail K, Gliniak B,
Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, et al:
Tumoricidal activity of tumor necrosis factor-related
apoptosis-inducing ligand in vivo. Nat Med. 5:157–163. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ashkenazi A, Pai RC, Fong S, Leung S,
Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert
A, et al: Safety and antitumor activity of recombinant soluble Apo2
ligand. J Clin Invest. 104:155–162. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mohr A, Lyons M, Deedigan L, Harte T, Shaw
G, Howard L, Barry F, O'Brien T and Zwacka R: Mesenchymal stem
cells expressing TRAIL lead to tumour growth inhibition in an
experimental lung cancer model. J Cell Mol Med. 12:2628–2643. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Menon LG, Kelly K, Yang HW, Kim SK, Black
PM and Carroll RS: Human bone marrow-derived mesenchymal stromal
cells expressing S-TRAIL as a cellular delivery vehicle for human
glioma therapy. Stem Cells. 27:2320–2330. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Grisendi G, Spano C, D'souza N, Rasini V,
Veronesi E, Prapa M, Petrachi T, Piccinno S, Rossignoli F, Burns
JS, et al: Mesenchymal progenitors expressing TRAIL induce
apoptosis in sarcomas. Stem Cells. 33:859–869. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dyer MJ, MacFarlane M and Cohen GM:
Barriers to effective TRAIL-targeted therapy of malignancy. J Clin
Oncol. 25:4505–4506. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Rieger J, Frank B, Weller M and Wick W:
Mechanisms of resistance of human glioma cells to Apo2
ligand/TNF-related apoptosis-inducing ligand. Cell Physiol Biochem.
20:23–34. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mahalingam D, Szegezdi E, Keane M, de Jong
S and Samali A: TRAIL receptor signalling and modulation: Are we on
the right TRAIL? Cancer Treat Rev. 35:280–288. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Naumann I, Kappler R, von Schweinitz D,
Debatin KM and Fulda S: Bortezomib primes neuroblastoma cells for
TRAIL-induced apoptosis by linking the death receptor to the
mitochondrial pathway. Clin Cancer Res. 17:3204–3218. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bianchi G, Morandi F, Cilli M, Daga A,
Bocelli-Tyndall C, Gambini C, Pistoia V and Raffaghello L: Close
interactions between mesenchymal stem cells and neuroblastoma cell
lines lead to tumor growth inhibition. PLoS One. 7:e486542012.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cussó L, Mirones I, Peña-Zalbidea S,
García-Vázquez V, García-Castro J and Desco M: Combination of
single-photon emission computed tomography and magnetic resonance
imaging to track 111in-oxine-labeled human mesenchymal stem cells
in neuroblastoma-bearing mice. Mol Imaging. 13:132014. View Article : Google Scholar
|
|
52
|
French R, Hayward O, Jones S, Yang W and
Clarkson R: Cytoplasmic levels of cFLIP determine a broad
susceptibility of breast cancer stem/progenitor-like cells to
TRAIL. Mol Cancer. 14:2092015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Schneider P, Thome M, Burns K, Bodmer JL,
Hofmann K, Kataoka T, Holler N and Tschopp J: TRAIL receptors 1
(DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate
NF-kappaB. Immunity. 7:831–836. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
LeBlanc H, Lawrence D, Varfolomeev E,
Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D and
Ashkenazi A: Tumor-cell resistance to death receptor - induced
apoptosis through mutational inactivation of the proapoptotic Bcl-2
homolog Bax. Nat Med. 8:274–281. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Deveraux QL, Takahashi R, Salvesen GS and
Reed JC: X-linked IAP is a direct inhibitor of cell-death
proteases. Nature. 388:300–304. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
56
|
Relation T, Yi T, Guess AJ, La Perle K,
Otsuru S, Hasgur S, Dominici M, Breuer C and Horwitz EM:
Intratumoral delivery of interferon γ-secreting mesenchymal stromal
cells repolarizes tumor-associated macrophages and suppresses
neuroblastoma proliferation in vivo. Stem Cells. 36:915–924. 2018.
View Article : Google Scholar : PubMed/NCBI
|
